vs
Side-by-side financial comparison of Baxter International (BAX) and Baidu, Inc. (BIDU). Click either name above to swap in a different company.
Baidu, Inc. is the larger business by last-quarter revenue ($5.0B vs $3.0B, roughly 1.7× Baxter International). Baidu, Inc. runs the higher net margin — 6.0% vs -37.9%, a 43.9% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 14.0%). Over the past eight quarters, Baidu, Inc.'s revenue compounded faster (7.5% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
Baidu, Inc. is a Chinese multinational technology company specializing in Internet services and artificial intelligence. It holds a dominant position in China's search engine market, and provides a wide variety of other internet services such as Baidu App, Baidu Baike, iQIYI, and Baidu Tieba.
BAX vs BIDU — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $5.0B |
| Net Profit | $-1.1B | $300.0M |
| Gross Margin | 19.4% | 41.0% |
| Operating Margin | -24.5% | 4.1% |
| Net Margin | -37.9% | 6.0% |
| Revenue YoY | 458.0% | 14.0% |
| Net Profit YoY | -120.3% | -47.1% |
| EPS (diluted) | $-2.21 | $0.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $5.0B | ||
| Q3 25 | $2.8B | $4.4B | ||
| Q2 25 | $2.8B | $4.6B | ||
| Q1 25 | $2.6B | $4.5B | ||
| Q4 24 | $533.0M | $4.4B | ||
| Q3 24 | $2.7B | $4.8B | ||
| Q2 24 | $3.8B | $4.7B | ||
| Q1 24 | $3.6B | $4.4B |
| Q4 25 | $-1.1B | $300.0M | ||
| Q3 25 | $-46.0M | $-1.6B | ||
| Q2 25 | $91.0M | $1.0B | ||
| Q1 25 | $126.0M | $1.1B | ||
| Q4 24 | $-512.0M | $567.0M | ||
| Q3 24 | $140.0M | $1.1B | ||
| Q2 24 | $-314.0M | $768.0M | ||
| Q1 24 | $37.0M | $811.0M |
| Q4 25 | 19.4% | 41.0% | ||
| Q3 25 | 33.5% | 41.2% | ||
| Q2 25 | 35.3% | 43.9% | ||
| Q1 25 | 32.8% | 46.1% | ||
| Q4 24 | 25.0% | 49.9% | ||
| Q3 24 | 38.3% | 51.1% | ||
| Q2 24 | 37.5% | 51.7% | ||
| Q1 24 | 38.6% | 51.5% |
| Q4 25 | -24.5% | 4.1% | ||
| Q3 25 | 6.1% | -48.4% | ||
| Q2 25 | 6.8% | 10.0% | ||
| Q1 25 | 2.2% | 13.9% | ||
| Q4 24 | -25.5% | 11.1% | ||
| Q3 24 | 5.7% | 17.6% | ||
| Q2 24 | -5.0% | 17.5% | ||
| Q1 24 | 5.2% | 17.4% |
| Q4 25 | -37.9% | 6.0% | ||
| Q3 25 | -1.6% | -36.3% | ||
| Q2 25 | 3.2% | 22.2% | ||
| Q1 25 | 4.8% | 24.1% | ||
| Q4 24 | -96.1% | 12.8% | ||
| Q3 24 | 5.2% | 23.2% | ||
| Q2 24 | -8.2% | 16.4% | ||
| Q1 24 | 1.0% | 18.6% |
| Q4 25 | $-2.21 | $0.53 | ||
| Q3 25 | $-0.09 | $-4.76 | ||
| Q2 25 | $0.18 | $2.84 | ||
| Q1 25 | $0.25 | $2.98 | ||
| Q4 24 | $-0.99 | $1.95 | ||
| Q3 24 | $0.27 | $3.08 | ||
| Q2 24 | $-0.62 | — | ||
| Q1 24 | $0.07 | $2.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $16.5B |
| Total DebtLower is stronger | $9.5B | $5.9B |
| Stockholders' EquityBook value | $6.1B | $38.1B |
| Total Assets | $20.1B | $64.2B |
| Debt / EquityLower = less leverage | 1.55× | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $16.5B | ||
| Q3 25 | $1.7B | $17.5B | ||
| Q2 25 | $1.7B | $17.3B | ||
| Q1 25 | $2.3B | $19.5B | ||
| Q4 24 | $1.8B | $17.5B | ||
| Q3 24 | $1.4B | $18.9B | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $3.0B | — |
| Q4 25 | $9.5B | $5.9B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.4B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | $10.4B | $4.9B | ||
| Q3 24 | $10.4B | $2.1B | ||
| Q2 24 | $10.4B | — | ||
| Q1 24 | $11.1B | — |
| Q4 25 | $6.1B | $38.1B | ||
| Q3 25 | $7.2B | $38.6B | ||
| Q2 25 | $7.3B | $39.8B | ||
| Q1 25 | $7.1B | $38.6B | ||
| Q4 24 | $7.0B | $36.1B | ||
| Q3 24 | $7.9B | $38.5B | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $8.2B | — |
| Q4 25 | $20.1B | $64.2B | ||
| Q3 25 | $21.1B | $62.4B | ||
| Q2 25 | $21.0B | $62.9B | ||
| Q1 25 | $21.3B | $62.6B | ||
| Q4 24 | $25.8B | $58.6B | ||
| Q3 24 | $26.7B | $59.5B | ||
| Q2 24 | $26.3B | — | ||
| Q1 24 | $27.8B | — |
| Q4 25 | 1.55× | 0.16× | ||
| Q3 25 | — | 0.07× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.06× | ||
| Q4 24 | 1.49× | 0.14× | ||
| Q3 24 | 1.33× | 0.05× | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $1.5B |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 5.08× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $1.5B | ||
| Q3 25 | $237.0M | — | ||
| Q2 25 | $217.0M | $-6.3B | ||
| Q1 25 | $-193.0M | — | ||
| Q4 24 | $488.0M | $4.0B | ||
| Q3 24 | $253.0M | — | ||
| Q2 24 | $115.0M | $5.3B | ||
| Q1 24 | $163.0M | — |
| Q4 25 | — | 5.08× | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.38× | -6.26× | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | 7.12× | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | — | 6.88× | ||
| Q1 24 | 4.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
BIDU
| Legacy Business | $1.8B | 35% |
| Baidu Core AI-powered Business | $1.6B | 32% |
| Other | $1.3B | 26% |
| Others | $357.5M | 7% |
